Med4Cure IPCEI: €1 Billion State Aid

The European Commission has approved up to €1 billion in State aid from six Member States for the first Important Project of Common European Interest (IPCEI) in the health sector, named IPCEI Med4Cure. This initiative aims to support research, innovation, and industrial deployment of healthcare products and pharmaceutical production processes. It aligns with the European Health Union’s goals by addressing diseases lacking effective prevention or treatment and enhancing the EU’s preparedness for health threats.

Objectives and Scope of IPCEI Med4Cure

1. Innovative Medical Advancements: Develop breakthrough therapies, including personalized treatments, and advanced digital technologies for the pharmaceutical value chain.
2. Sustainable Production: Create sustainable production processes for pharmaceuticals, improving drug discovery and addressing unmet medical needs such as rare diseases.
3. Enhance EU Health Industry: Increase resilience and preparedness for emerging health threats while contributing to the green transition.

Collaboration and Impact of IPCEI Med4Cure

The project, jointly notified by Belgium, France, Hungary, Italy, Slovakia, and Spain, will involve 14 innovative projects by 13 companies, including nine SMEs. The public funding is expected to leverage an additional €5.9 billion in private investments, fostering around 6,000 direct and indirect jobs. The ecosystem includes collaborations with over 175 indirect partners, such as universities and research organizations.

Completion of the IPCEI is planned for 2036, aiming to significantly enhance healthcare quality and the EU’s readiness for future health challenges. The initiative promises positive spillover effects throughout Europe, with widespread sharing of project results.

The European Commission evaluated the project under EU State aid rules, ensuring it supports ambitious technological advancements and addresses significant financial and technological risks. Aid is proportionate and necessary, avoiding undue market distortions. Successful projects may return part of the aid through a claw-back mechanism.

FI Group has been promoting innovation for 20 years, helping from startups to large corporations in the financing of R&D&I at a global level. We advise companies on the management of their R&D&I financing, through the design and implementation of actions aimed at boosting their technological and economic development. Our eagerness to achieve excellence in all our services has led us to assume leadership in the sector, both at national and European level.

Teresa Marina